Discovery and development of antibody therapies for COVID-19
22 Apr 2021

Neutralizing antibodies (nAbs) against SARS-CoV-2 represent a promising option for treating COVID-19. Screening a large and diverse antibody phage library has allowed for the rapid discovery of anti-SARS-CoV-2 nAbs.

In this expert webinar, find out how high-throughput epitope binning and mapping using label-free biolayer interferometry (BLI) detection and advanced flow cytometry systems has enabled the development of an antibody cocktail that can reduce the risk of drug resistance.

Key learning objectives:

  • Describe how neutralizing antibodies can be used as a drug modality for the treatment of COVID-19
  • Identify components of SARS-CoV-2 relevant to resistance against antibody therapy
  • Evaluate strategies for the discovery and development of neutralizing antibodies for research applications

Who should attend?

  • Biopharma and biotech representatives
  • Novel vaccine and treatment developers
  • Researchers interested in DNA/RNA

Sartorius Group